SLC9A1 Binding mTOR Signaling Pathway-Derived Risk Score Predicting Survival and Immune in Clear Cell Renal Cell Carcinoma

Objective. Clear cell renal cell carcinoma (ccRCC) is one of the common renal cell carcinomas (RCC) with a high risk of recurrence. Considering that SLC9A1 is involved in various cellular physiological processes and probably mediates the course of mTOR signaling in tumors, this study constructed a risk model for SLC9A1 combined with mTOR signaling in ccRCC, aiming at better predicting the prognosis of patients. Methods. ccRCC expression matrices were downloaded from TCGA and ICGC databases to compare the expression of SLC9A1 in TCGA, and qRT-PCR was adopted to validate the SLC9A1 expression in different RCC cells and normal kidney cells. The CIBERSORT and ESTIMATE algorithms were used to assess samples for immunity. mTOR signaling-associated genes were downloaded from the KEGG website, and then the genes were adopted to screen genes associated with SLC9A1 expression and mTOR signaling pathway colleagues, based on which univariate COX regression and lasso regression Cox analyses were conducted to construct a ccRCC prognostic risk model. ROC curves and nomograms were used to assess the validity of the models. Results. ccRCC tumor samples showed lower SLC9A1 expression than normal samples, as also evidenced by qRT-PCR. The SLC9A1 expression was highly correlated with tumor immunity. Totally, 564 key genes associated with both SLC9A1 expression and mTOR signaling were screened out, and the risk model consisting of 11 gene signatures was constructed in ccRCC based on the 564 genes. Since patients at a high risk had poorer survival outcomes, the high-risk group presented poorer immunotherapy outcomes. Moreover, a higher clinical grade of patients suggested a higher risk score. The risk score can serve as one independent prognostic factor for the prognosis prediction of ccRCC patients. Conclusion. An extremely promising prognostic indicator for ccRCC based on SLCA9A1 and mTOR signaling has been constructed to provide reference for clinical treatment.

[1]  Xiangqian Guo,et al.  A Comprehensive Prognostic Analysis of Tumor-Related Blood Group Antigens in Pan-Cancers Suggests That SEMA7A as a Novel Biomarker in Kidney Renal Clear Cell Carcinoma , 2022, International journal of molecular sciences.

[2]  Limin Ma,et al.  EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms , 2022, European Journal of Medical Research.

[3]  Zhicheng Zhang,et al.  Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. , 2022, International immunopharmacology.

[4]  F. Ai,et al.  MicroRNA-4735-3p Facilitates Ferroptosis in Clear Cell Renal Cell Carcinoma by Targeting SLC40A1 , 2022, Analytical cellular pathology.

[5]  Haowen Jiang,et al.  Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma , 2022, Frontiers in Immunology.

[6]  Xi Wu,et al.  Hsa_circ_0007967 promotes gastric cancer proliferation through the miR-411-5p/MAML3 axis , 2022, Cell death discovery.

[7]  Caigang Liu,et al.  Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer , 2022, eLife.

[8]  Qianwei Xing,et al.  Survival Prognosis, Tumor Immune Landscape, and Immune Responses of PPP1R18 in Kidney Renal Clear Cell Carcinoma and Its Potentially Double Mechanisms , 2022, World journal of oncology.

[9]  Ping Zhang,et al.  The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability , 2022, Experimental & molecular medicine.

[10]  L. Fliegel,et al.  Permissive role of Na+/H+ exchanger isoform 1 in migration and invasion of triple-negative basal-like breast cancer cells , 2022, Molecular and Cellular Biochemistry.

[11]  Meiyi Song,et al.  Key genes associated with prognosis and metastasis of clear cell renal cell carcinoma , 2021, PeerJ.

[12]  Leif Oxburgh,et al.  The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma Determines Cancer Associated Fibroblast Growth , 2021, Cancers.

[13]  J. Foster,et al.  Sodium hydrogen exchanger (NHE1) palmitoylation and potential functional regulation. , 2021, Life sciences.

[14]  Zhengtian Li,et al.  Identification and validation of a hypoxia-related prognostic signature in clear cell renal cell carcinoma patients , 2021, Medicine.

[15]  Yumei Liang,et al.  Identification of Prognostic Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma , 2021, Journal of oncology.

[16]  Xiaodong Yang,et al.  Na+/H+-Exchanger Family as Novel Prognostic Biomarkers in Colorectal Cancer , 2021, Journal of oncology.

[17]  Bao Hou,et al.  Type-1 Na+/H+ exchanger is a prognostic factor and associate with immune infiltration in liver hepatocellular carcinoma. , 2021, Life sciences.

[18]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[19]  Rong Cong,et al.  Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma , 2021, Cancer cell international.

[20]  L. Foley,et al.  Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells , 2021, Theranostics.

[21]  F. Lozupone,et al.  TM9SF4 expression in tumor tissues: a novel diagnostic biomarker for gastrointestinal tumors , 2020, Translational cancer research.

[22]  B. Rini,et al.  The immunology of renal cell carcinoma , 2020, Nature Reviews Nephrology.

[23]  K. Bensalah,et al.  Immunotherapy in Renal Cell Carcinoma: The Future Is Now , 2020, International journal of molecular sciences.

[24]  M. Atkins,et al.  Checkpoint inhibitor immunotherapy in kidney cancer , 2020, Nature Reviews Urology.

[25]  D. Sabatini,et al.  mTOR at the nexus of nutrition, growth, ageing and disease , 2020, Nature Reviews Molecular Cell Biology.

[26]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2020, Cell.

[27]  C. Capurro,et al.  Na+/H+ exchanger isoform 1 activity in AQP2-expressing cells can be either proliferative or anti-proliferative depending on extracellular pH , 2019, Journal of Physiology and Biochemistry.

[28]  T. Conrads,et al.  Ancestral characterization of 1018 cancer cell lines highlights disparities and reveals gene expression and mutational differences , 2019, Cancer.

[29]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[30]  Dandan Sun,et al.  Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas , 2018, Journal of experimental & clinical cancer research : CR.

[31]  Yue Zhang,et al.  SERPINH1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker , 2017, Journal of cellular and molecular medicine.

[32]  B. Rini,et al.  Treatment of renal cell carcinoma: Current status and future directions , 2017, CA: a cancer journal for clinicians.

[33]  R. Xie,et al.  NHE1 is upregulated in gastric cancer and regulates gastric cancer cell proliferation, migration and invasion. , 2017, Oncology reports.

[34]  T. Choueiri,et al.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[36]  P. Vallés,et al.  Physiological Functions and Regulation of the Na+/H+ Exchanger [NHE1] in Renal Tubule Epithelial Cells , 2015, Kidney and Blood Pressure Research.

[37]  G. Mills,et al.  The PI3K/AKT Pathway and Renal Cell Carcinoma. , 2015, Journal of genetics and genomics = Yi chuan xue bao.

[38]  M. Cuello,et al.  NHE1 PROMOTE CELL PROLIFERATION IN OVARIAN CANCER: A ROLE OF HYPOXIA-INDUCIBLE FACTORS.: IGCS-0038 06. Ovarian Cancer. , 2015, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[39]  P. van der Bruggen,et al.  Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines , 2011, Cancers.

[40]  D. Good,et al.  Nerve growth factor inhibits Na+/H+ exchange and formula absorption through parallel phosphatidylinositol 3-kinase-mTOR and ERK pathways in thick ascending limb. , 2008, The Journal of biological chemistry.

[41]  G. Rubin,et al.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences , 2002, Proceedings of the National Academy of Sciences of the United States of America.